Curetis to benefit from bioMérieux's BioFire swoop?
This article was originally published in Clinica
Executive Summary
Infectious disease molecular diagnostics specialist Curetis has seen increasing interest in its technology from some of the larger players since the acquisition of rival BioFire Diagnostics by France’s bioMérieux. The Marcy l’Etoile shelled out $450m, plus debt, for BioFire and its FilmArray platform earlier this month, in a deal that was too rich for some analysts (www.clinica.co.uk, 5 September 2013).